Abemaciclib monarchE



Abemaciclib monarchE Abemaciclib monarchE PRFLIMINARY SCORE **SCORE CURATIVE CURATIVE** DFS Overall Survival / Disease-Free Survival / Pathological Complete Response **NON-CURATIVE NON-CURATIVE** Overall Survival **ADJUSTMENTS** Quality of life Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response Other adjustments INFORMATION Therapeutic Indication: In combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor positive, HER2- negative, node positive early breast cancer at high risk of recurrence and a Ki-67 score >20% In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone agonist Experimental Arm: Abemaciclib + Standard endocrine therapy (aromatase inhibitors and/or antiestrogens with or without ovarian suppression) Control Arm: Standard endocrine therapy



© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.